Real-world evidence from a european cohort study of patients with treatment resistant depression: healthcare resource utilization

Heerlein, K.; De Giorgi, S.; Degraeve, G.; Frodl, T.; Hagedoorn, W.; Oliveira Maia, A. J.; Otte, C.; Pérez Solà, Víctor; Rathod, S.; Rosso, G.; Sierra, Pablo; Vita , A.; Morrens, J.; Rive, B.; Mulhern Haughey S.; Kambarov, Y.; Young, Allan H.

doi:http://dx.doi.org/10.1016/j.jad.2021.11.004

Real-world evidence from a european cohort study of patients with treatment resistant depression: healthcare resource utilization

License

Citation

Heerlein K, De Giorgi S, Degraeve G, Frodl T, Hagedoorn W, Oliveira-Maia AJ, et al. Real-world evidence from a european cohort study of patients with treatment resistant depression: healthcare resource utilization. Disord. 2022 Feb 1; 298(Pt A): 442-450. DOI: 10.1016/j.jad.2021.11.004.

Abstract

Background: treatment resistant depression (TRD) is diagnosed when patients experiencing a major depressive episode fail to respond to ≥2 treatments. Along with substantial indirect costs, patients with TRD have higher healthcare resource utilization (HCRU) than other patients with depression. However, research on the economic impact of this HCRU, and differences according to response to treatment, is lacking. Methods: this multicenter, observational study documented HCRU among patients with TRD in European clinical practice initiating new antidepressant treatments. Data regarding access to outpatient consultations and other healthcare resources for the first 6 months, collected using a questionnaire, were analyzed qualitatively according to response and remission status. The economic impact of HCRU, estimated using European costing data, was analyzed quantitatively. Results: among 411 patients, average HCRU was higher in non-responders, attending five times more general practitioner (GP) consultations and spending longer in hospital (1.7 versus 1.1 days) than responders. Greater differences were observed according to remission status, with non-remitters attending seven times more GP consultations and spending approximately three times longer in hospital (1.7 versus 0.6 days) than remitters. Consequently, the estimated economic impacts of non-responders and non-remitters were significantly greater than those of responders and remitters, respectively. Limitations: key limitations are small cohort size, absence of control groups and generalizability to different healthcare systems. Conclusion: patients with TRD, particularly those not achieving remission, have considerable HCRU, with associated economic impact. The costs of unmet TRD treatment needs are thus substantial, and treatment success is fundamental to reduce individual needs and societal costs.